SCHEMBL3554648

SCHEMBL3554648

NS(=O)(=O)c1cc2c3c(ccc2cc1[N+](=O)[O-])N(C(=O)C(F)(F)F)CC3CCl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
CA7 P43166 1/20 0.37
ADH1A P07327 1/20 0.37
KIT P10721 1/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
ABL2 P42684 1/20 0.37
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567553 0.87 ADH1A (0.38) MAPTALDH1A1CA12CA1CA2
SCHEMBL3562630 0.82 SIRT6 (0.36) MAPTALDH1A1ADH1AKITFLT1
SCHEMBL13345018 0.81 ADH1A (0.31) ADH1AKITFLT1FLT4KDR
SCHEMBL3569942 0.80 ADH1A (0.36) MAPTALDH1A1ADH1AKITFLT1
SCHEMBL3562214 0.80 CA2 (0.42) MAPTALDH1A1CA12CA1CA2
SCHEMBL3555079 0.80 CA2 (0.42) MAPTALDH1A1CA12CA1CA2
SCHEMBL3559296 0.77 CA12 (0.37) CA12CA1CA2CA9CA7
SCHEMBL3558756 0.76 ADH1A (0.32) MAPTALDH1A1ADH1AKITFLT1
SCHEMBL3564653 0.76 ADH1A (0.49) MAPTALDH1A1ADH1AKITFLT1
SCHEMBL3555601 0.76 ADH1A (0.39) MAPTALDH1A1ADH1AKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A MAPT 4792/4885ALDH1A1 77/4885CA12 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.